skip to main content

NSCLC — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardLung CancerNSCLCSCE Medical Oncology

After complete resection and platinum chemotherapy for high-risk NSCLC, a patient has PD-L1 TPS 65% and no EGFR mutation or ALK rearrangement. Which option exactly satisfies the biomarker-specific eligibility in NICE TA1071?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Adjuvant atezolizumab for PD-L1-high EGFR- and ALK-negative disease under TA1071

TA1071 recommends atezolizumab after complete resection and platinum chemotherapy for high-risk recurrence when PD-L1 expression is at least 50% and EGFR and ALK alterations are absent. Durvalumab is associated with unresectable stage III chemoradiation, osimertinib requires a sensitising EGFR mutation, and nivolumab does not replace the appraisal criteria. Other adjuvant options may also be clinically suitable, but the question asks specifically for TA1071 eligibility.

Reference: NICE TA1071 atezolizumab after complete resection of NSCLC (Published June 2025): https://www.nice.org.uk/guidance/ta1071/chapter/1-Recommendations